Bioprinting of Patient-Specific Multiple Myeloma Models for Personalized Treatment

The treatment of Multiple Myeloma (MM) is hindered by high genetic heterogeneity, where the unique DNA profile of each patient's plasma cells leads to varied drug responses. Developing personalized 3D-printed tissues, is critical for testing treatments outside the patient’s body. This session describes an automated biofabrication workflow that utilizes a humanized and chemically defined extracellular matrix (ECM) bioink. We achieved the transition from manual cell culture to an automated 96-well format using a multi-nozzle bioprinter by optimization of a custom G-code sequence that coordinates three distinct stages: pneumatic extrusion of the cell-laden bioink, UV-light crosslinking to solidify the structure, and automated media dispensing for nutrient delivery. Results show that this standardized process produces an average of 122 organoids per patient sample. Technical stability is confirmed by maintaining over 70% cell viability and consistent multi-cellular phenotypes for seven days. Finally, we reviewed chemosensitivity data from screenings of standard-of-care drugs, demonstrating the model's ability to capture patient-specific drug resistance. We have now described the requirements for scaling bioink extrusion for high-throughput applications and gain insights into the mechanical and biological parameters necessary to keep primary human cells viable within a 3D-printed architecture.